Tristel (TSTL)

Sector:

Health Care

Index:

FTSE AIM 100

415.00p
   
  • Change Today:
      2.50p
  • 52 Week High: 500.00
  • 52 Week Low: 270.00
  • Currency: UK Pounds
  • Shares Issued: 47.71m
  • Volume: 91,134
  • Market Cap: £198.00m
  • RiskGrade: 180

Tristel submits additional details for FDA disinfectant clearance

By Josh White

Date: Thursday 10 Apr 2025

LONDON (ShareCast) - (Sharecast News) - Tristel announced on Thursday that it has submitted the additional information requested by the US Food and Drug Administration for its Tristel OPH disinfectant, moving the product closer to potential FDA clearance, which it now expects by the end of June.
The AIM-traded firm described Tristel OPH as a high-level disinfectant foam designed for use on ophthalmic medical devices, including reusable tonometers, pachymeters, and lenses that contact the cornea.

It said the FDA filing referenced Tristel ULT, a similar disinfectant cleared by the agency in June 2023 for use on ultrasound probes, as the predicate device under the 510(k) process.

The company said it believed FDA approval for Tristel OPH could significantly change ophthalmic disinfection practices in North America.

It said many semi-critical ophthalmic devices in the US were currently disinfected with lower-level solutions such as alcohol wipes or soaked in sodium hypochlorite or hydrogen peroxide, which are less effective and time-consuming.

Tristel said its product offered a more efficient alternative that could address long-standing operational inefficiencies in the sector.

Tristel added that around 16 million ultrasound procedures are performed annually in North America, underlining the potential market for high-level disinfection products in clinical settings.

"We are extremely pleased to have submitted the additional information to the FDA for Tristel OPH," said chief executive officer Matt Sassone.

"The ophthalmic opportunity within the US remains strong and we continue to make good progress on establishing our commercial route to market.

"With the timing of submission, a month ahead of the ultimate deadline, we have given ourselves the best opportunity to have the FDA decision in time for the Association for Professionals in Infection Control and Epidemiology conference in Phoenix, Arizona mid-June, the largest annual event in the USA for reaching critical Infection Preventionist community and decision makers."

At 1205 BST, shares in Tristel were up 4.96% at 307p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Tristel Market Data

Currency UK Pounds
Share Price 415.00p
Change Today 2.50p
% Change 0.61 %
52 Week High 500.00
52 Week Low 270.00
Volume 91,134
Shares Issued 47.71m
Market Cap £198.00m
RiskGrade 180

Tristel Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
95% below the market average95% below the market average95% below the market average95% below the market average95% below the market average
87.88% below the sector average87.88% below the sector average87.88% below the sector average87.88% below the sector average87.88% below the sector average
Price Trend
6.69% below the market average6.69% below the market average6.69% below the market average6.69% below the market average6.69% below the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
Income
13.81% above the market average13.81% above the market average13.81% above the market average13.81% above the market average13.81% above the market average
75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average
Growth
85.37% above the market average85.37% above the market average85.37% above the market average85.37% above the market average85.37% above the market average
94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 3
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Tristel Dividends

  Latest Previous
  Interim Final
Ex-Div 20-Mar-25 28-Nov-24
Paid 11-Apr-25 20-Dec-24
Amount 5.68p 8.28p

Trades for 11-Jul-2025

Time Volume / Share Price
13:13 42,344 @ 411.53p
16:10 882 @ 417.00p
16:10 882 @ 417.00p
15:50 1,400 @ 413.50p
15:47 562 @ 413.50p

Tristel Key Personnel

CEO Matthew (Matt) Giovanni Sassone

Top of Page